Beyond AREDS2:
3 Natural Compounds
With Clinical AMD Data Most Patients Are Never Told About
If you’ve been told “AREDS2 is all you can do,” you’re not alone. Harvard, Mayo Clinic, and Nordic research
has uncovered a 3-compound pathway that may offer meaningful protection — but the extraction method
matters as much as the compounds themselves.
Three Compounds: Wild Nordic Blueberry Anthocyanins, Zeaxanthin, and Astaxanthin.
Processing Matters: cryogenic extraction preserves up to 99% of active compounds.
AREDS2 Gap: formulated in the 1990s — before daily screen exposure became baseline.
Heat-drying can destroy ~80% of anthocyanins during production.
What AREDS2 Was Designed to Do — and What It Wasn’t
AREDS2 remains a clinically validated baseline for many patients. But it was formulated in the 1990s and does not include
compounds now studied for screen-related oxidative stress and retinal bioavailability.
A common misconception is that “the ingredient list is all that matters.” In practice, the extraction method determines
whether these compounds actually reach the retina in meaningful amounts.
KEY INSIGHT
“Two products can have the same label — but if the plant compounds were heat-dried, you may be getting a fraction of the usable content.”
— as explained in Dr. Wang’s presentation
The Three Compounds — A Clinical Breakdown
1
BLUEBERRY ANTHOCYANINS
Wild Nordic Blueberry Anthocyanins
Clinical evidence supports a specific class of anthocyanins concentrated in wild Nordic blueberries.
The issue: standard processing can destroy the majority of these actives.
Cryogenic extraction (sub-zero temperatures) is used to preserve bioavailability.
Zeaxanthin supports macular pigment density, a key component in filtering high-energy light.
Many formulas contain lutein but under-dose or omit zeaxanthin — despite post-AREDS2 data suggesting
a different balance may matter for modern exposure patterns.
Macular pigmentBlue light filteringPost-AREDS2
3
ASTAXANTHIN
Astaxanthin (from red marine algae)
Astaxanthin has been studied for oxidative stress modulation. In clinical tracking contexts,
it is often paired with anthocyanins to support retinal resilience — especially when screen exposure is high.
Oxidative stressRetinal resilienceScreen exposure
Why the Extraction Method Changes Everything
Standard heat-drying can destroy approximately 80% of anthocyanin content during production.
Cryogenic extraction preserves the actives, which can translate into substantially different retinal availability.
HEAT-DRIED (TYPICAL)
20%
Approximate active content retained after processing.
CRYOGENIC EXTRACTION
99%
Active compounds preserved in sub-zero extraction.
BOTTOM LINE
If you’ve tried “blueberry supplements” with no results, it may not be the compound — it’s the method.
That’s why patients can take a product for months and never reach a meaningful retinal dose.
How the Three Compounds Compare to Standard AREDS2
Compound
Common Source
Typical Issue
Why It Matters
Wild Nordic Blueberry Anthocyanins
Bilberry / Wild blueberry
Heat-drying destroys actives
Bioavailability can change dramatically
Zeaxanthin
Marigold
Often under-dosed or omitted
Supports macular pigment density
Astaxanthin
Red marine algae
Often not paired correctly
Oxidative stress support for retina
AREDS2
Vitamins/minerals baseline
1990s formula; missing newer compounds
Still useful — but may not cover modern gaps
The Practical Takeaway
The key isn’t “replace everything.” It’s understanding what is missing — and why extraction method determines whether the retina receives the dose
that clinical tracking suggests is needed.
The complete Eye Rebirth Effect protocol — including which compounds Harvard researchers studied, the extraction method, and how to discuss it with your doctor.
Presentation available while current patient slots remain open
Common Questions About Natural AMD Treatment
Clinical evidence supports three specific natural compounds processed cryogenically: Wild Nordic Blueberry Anthocyanins (750mg/day),
Lutein and Zeaxanthin from marigold, and Astaxanthin from red marine algae (12mg/day). A Harvard 2023 study of 550+ AMD patients using this combination reported 96% improvement in 21 days.
Processing method is critical — heat-dried versions retain only 20% of the active content.
AREDS2 remains clinically validated as a baseline, but it was formulated in the 1990s and does not include Wild Nordic Blueberry Anthocyanins or Astaxanthin —
two compounds with significant post-AREDS2 clinical data. It also doesn't account for the extraction method that determines how much of any compound actually reaches the retina.
Standard heat-drying destroys approximately 80% of the Anthocyanin content during production. Cryogenic extraction, at sub-zero temperatures, preserves 99% of the active compounds.
This 5-fold difference in bioavailability explains why many patients see no result from commercially available blueberry supplements despite consistent use.
Evidence supports meaningful slowing of AMD progression and, in some clinical contexts, measurable improvement in visual function through targeted nutritional intervention.
The Harvard 2023 study (N=550+) reported 96% improvement in 21 days. The Mayo Clinic Astaxanthin study (N=254) found macular cells functioning as if 8–10 years younger after 90 days.
These findings indicate a substantially larger role for nutrition in AMD management than the standard of care currently reflects.